Our story

Founded in 2002, we are a clinical stage biotech company committed to the discovery and development of novel and effective therapeutics for the treatment of cancer.

We leverage our deep expertise in oncology focused novel therapeutics for the benefit of cancer patients everywhere.

Our story

Founded in 2002, we are a clinical stage biotech company committed to the discovery and development of novel and effective therapeutics for the treatment of cancer.

We leverage our deep expertise in oncology focused novel therapeutics for the benefit of cancer patients everywhere.

Video of our Journey

Play Video

Our approach

We focus on developing innovative therapeutics addressing several hallmarks of cancer, leveraging our deep capabilities in science and building value added collaborations with leading companies globally.

drug development

Our impact

We have built comprehensive drug discovery and development capabilities, nurtured a growing team of passionate scientists, and collaborated with partners from across the world.

Media center

Get the latest updates from Aurigene in the news, conferences, events, and more.

October 8, 2024

Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy...

new drug development

September 24, 2024

September 30- October 3, 2024, Discovery on Target

Get in touch with us:

Our publications

Explore our vast body of work in oncology research, innovative technology and therapeutics.

Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical Cancer Models

Discovery and Development of pan-KRAS Degraders for Cancer Therapy